Overexpression of PRDX2 alleviates chronic thromboembolic pulmonary hypertension by modulating inflammation and mitophagy Authors: Chen Gong, Xiaoyan Lan, Yiming Xie, Xiaobing Wu, Fengxia Wu, Xing Chen, Huilei Zheng, Hong Wen, Feng Huang, Zhiyu Zeng Published: 2025 ABSTRACT AbstractChronic thromboembolic pulmonary hypertension (CTEPH) results from thrombi-induced endothelial injury, inflammation, and oxidative stress in pulmonary vessels, leading to vascular remodelling, increased resistance, and elevated pulmonary arterial pressure. Peroxiredoxin 2 (PRDX2) is an antioxidant enzyme involved in regulating cellular redox balance and inflammation, its role in CTEPH is not yet fully understood. The aim is to investigate the expression and functional role of PRDX2 in CTEPH and explore its potential mechanisms in modulating inflammation and mitochondrial autophagy. Proteomics was used to analyse peripheral blood samples from patients with CTEPH and healthy controls to identify differentially expressed proteins. A rat model of CTEPH was developed through the intravenous injection of amino-crosslinked polystyrene microspheres. PRDX2 expression was assessed in lung tissues and primary pulmonary artery endothelial cells (PAECs) using immunohistochemistry, Western blotting, and qRT-PCR. The effects of PRDX2 overexpression and silencing on inflammation and mitochondrial autophagy were evaluated using ELISA, Western blotting, and transmission electron microscopy. The expression of PRDX2 was significantly increased in the peripheral blood of patients with CTEPH and in the pulmonary vasculature of rats with CTEPH.Overexpression of PRDX2 in PAECs attenuated the inflammatory response by NF-κB signaling pathway. Additionally, overexpression of PRDX2 regulated the expression of mitophagy-related proteins (LC3II/I, Beclin-1, and p62) and restored mitochondrial morphology. Further verification in rats showed that PRDX2 overexpression significantly improved haemodynamic parameters and pulmonary vascular remodelling in CTEPH. Overexpression of PRDX2 alleviates pulmonary vascular remodeling in CTEPH by reducing inflammation and Modulating mitophagy, suggesting its protective role and potential as a therapeutic target for the disease.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-31063-5.Keywords: Chronic thromboembolic pulmonary hypertension, Peroxiredoxin 2, Inflammation, Mitochondrial autophagy, Pulmonary artery endothelial cellsSubject terms: Cell biology, Molecular biology, Molecular medicine Introduction Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe pulmonary vascular disease with a low survival rate and a poor prognosis1,2. The etiology of CTEPH is complex, primarily resulting from the incomplete dissolution of thrombi in the pulmonary arteries, which leads to vascular obstruction and remodeling. This, in turn, contributes to increased pulmonary artery pressure3. Inflammatory thrombi, which form in an inflammatory microenvironment and are resistant to the body’s removal, may be closely associated with thrombus insolubility4,5. Furthermore, patients with pulmonary hypertension often experience inflammatory responses and oxidative stress6, which can damage mitochondria. Mitochondrial autophagy, acting as a cellular stress response, can regulate levels of inflammation and oxidative stress while eliminating damaged mitochondria7–9. However, the mechanisms underlying the development of CTEPH are not well understood, and there is an urgent need for in-depth studies to clarify its pathophysiological processes and to provide more effective clinical treatment strategies. Peroxiredoxin 2 (PRDX2) is an important antioxidant enzyme that is widely distributed throughout the cytoplasm and mitochondria10,11 and is involved in a variety of cell signalling pathways12. It modulates redox signaling pathways by controlling intracellular hydrogen peroxide levels, thereby influencing cell proliferation, apoptosis, and inflammatory responses13–15. Additionally, PRDX2 may also impact intracellular signaling networks through interactions with a range of proteins16.PRDX2 also plays an important role in the immune system17. It attenuates inflammatory damage by scavenging peroxides produced at the site of inflammation, and dysfunction of PRDX2 has been linked to the development of various diseases18. For example, in cancer, aberrant expression of PRDX2 may affect tumour cell proliferation and drug resistance19–21; in neurodegenerative diseases, aberrant expression of PRDX2 may be associated with oxidative damage in neurons22. In cardiovascular disease, impaired antioxidant function of PRDX2 may lead to vascular endothelial cell injury23. The role of PRDX2 has been extensively studied in relation to various diseases. However, its role in CTEPH is unclear. Given that patients with CTEPH are often associated with inflammatory responses and oxidative stress24, the potential role of PRDX2 in CTEPH deserves in-depth investigation to further elucidate its mechanism in disease development. This study aimed to investigate the role of PRDX2 and its potential mechanisms in CTEPH. Initially, proteomic analysis indicated that PRDX2 expression was significantly elevated in the peripheral blood of CTEPH patients. We also developed a rat model of CTEPH and observed that the animals exhibited the characteristic pathological features of pulmonary hypertension, including increased right ventricular pressure, pulmonary artery remodeling, and inflammatory responses. In the CTEPH rat model, PRDX2 was highly expressed in the endothelium of the pulmonary vasculature and was primarily localized in the cytoplasm of endothelial cells. In vitro experiments confirmed that PRDX2 expression levels in primary pulmonary artery endothelial cells were consistent with those observed in lung tissue. Moreover, we discovered that PRDX2 overexpression mitigated the inflammatory response in the CTEPH model and improved endothelial cell dysfunction by regulating mitochondrial autophagy. This study elucidates the potential role of PRDX2 in CTEPH, offering a novel therapeutic target. Materials and methods Human samples Peripheral blood was obtained from individuals with CTEPH (n = 6) and healthy controls (n = 6). The informed consent was obtained from all participants involved in this study.This study was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University(Nanning, China; approval no. 2024-S946-01). All procedures involving human participants were conducted in accordance with the Declaration of Helsinki and relevant national regulations.A summary of the detailed clinical information for each participant can be found in Supplementary Table S1. Data independent acquisition quantitative proteomics The first steps of our label-free quantitative proteomics study were protein extraction, quantification, digestion using enzymes, and analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS). This was followed by database searching and data analysis.The database used was UniProtKB-Homo sapiens (Human) [9606], downloaded on March 26, 2024, from the UniProt website (https://www.uniprot.org/taxonomy/9606). Proteins with expression changes greater than 1.5-fold were considered significantly differentially expressed. This was whether they were upregulated or downregulated. The P-value had to be less than 0.05. ELISA Levels of PRDX2 in human peripheral blood were measured using an enzyme-linked immunosorbent assay (ELISA). The serum was separated from the whole blood by centrifugation at 3,000 g for 15 min at 4℃. A PRDX2 ELISA kit (Cloud-Clone Corp, China) was used to determine PRDX2 concentrations, with this being done in accordance with the instructions provided by the manufacturer. Animals Male Sprague-Dawley(SD) rats (aged between 6 and 8 weeks) were obtained from the Laboratory Animal Center of Guangxi Medical University (Nanning, China). The animals were kept in a controlled environment with a 12-hour light/dark cycle and a temperature of 20–25 °C. They had free access to standard laboratory food and water.Rats were acclimated to the housing conditions for 1 week prior to any surgical or experimental interventions to minimize stress. All animal procedures were approved by the Animal Ethics Committee of Guangxi Medical University and were conducted in accordance with the ethical guidelines for the use of experimental animals.Rats received a slow intravenous injection of 1 ml of amino-crosslinked polystyrene microspheres (concentration: 25 mg/ml, particle size: 125–150 μm, Shanghai, China) via the tail vein. During the injection, rats were monitored for signs of rapid breathing and cyanosis of the lips. The control animals were injected with 1 ml of 0.9% saline, utilising the identical injection protocol.To achieve the in vivo overexpression of the target protein PRDX2, we used recombinant adeno-associated virus serotype 6 (AAV6) vectors. The experiment involved the intravenous injection of two groups of male rats, aged between six and eight weeks, with either AAV6 empty vector or AAV6 OE-PRDX2 vector (Hanbio, Shanghai, China). Three weeks later, the rats underwent the microsphere injection protocol described above to induce pulmonary embolism.After 12 weeks, all rats were assessed for cardiac function and right ventricular pressure. Subsequently, the animals were sacrificed following aortic exsanguination,, and samples of heart and lung tissues were collected for further analysis. Echocardiography Echocardiographic examinations were performed on the depilated precordium of rats using the Resona 7 ultrasound system (Mindray, China). The induction of anaesthesia was initiated in rats with 4% isoflurane, followed by maintenance with 2% isoflurane. Heart rates were monitored throughout the procedure, with values typically exceeding 200–300 bpm following induction. Right ventricular systolic pressure (RVSP) After anaesthesia, rats were tracheally intubated and connected to ventilator-assisted ventilation.The chest was then opened and the heart was exposed, and a 25G needle (Terumo, Japan) was used to puncture the right ventricle. A pressure catheter was inserted along the puncture needle hole and then connected to the pressure sensor system. (MPA, China), as previously described25. H&E,Masson,immunohistochemistry and Immunofluorescence staining Lung tissue was sectioned along the bronchial alignment and stained with hematoxylin and eosin (H&E), and α-smooth muscle actin (α-SMA) was stained immunohistochemically and immunofluorescently for pulmonary vascular lesions. Collagen content in the pulmonary arteries was assessed using Masson trichrome staining. The data were quantified using ImageJ software. qRT‒PCR Cellular total RNA was isolated with Trizol reagent, followed by reverse transcription quantitative PCR(RT-qPCR) analysis using SYBR Green on a real-time PCR instrument(Bio-Rad, USA).The relative levels of mRNA expression were determined via the 2 − ΔΔCt method, using β-actin as the internal reference. The sequences of the primers are listed in Supplementary Table S2. Western blotting Proteins were extracted from cells and lung tissues using RIPA buffer with PMSF(Solarbio, China) at a ratio of 100:1. Denatured protein samples were resolved by 10% SDS-PAGE (P2012, NCM Biotech) and transferred to PVDF membranes (Millipore, USA). The membranes were blocked with 3% BSA solution (Solarbio, China) and incubated overnight at 4℃ with the following primary antibodies: PRDX2(1:1000, Abways, China), BECN1(1:10000,Abcam, UK), P62(1:1000,Abways, China), LC3B(1:1000, Abways, China), tublin( 1:10,000,Affinity, China).Then, the membranes were incubated with a goat anti-rabbit IgG secondary antibody (1:10,000,Affinity, China) diluted at room temperature for 1 h.The catalog numbers for the chemicals used in the study are provided in Table S3.The membrane were then subjected to visualisation using the Proteinsimple FluorChem FC3 system (Silicon Valley, USA). Subsequently, the blots were quantified using ImageJ software. Culture of PAECs The main pulmonary artery was isolated from SD rats and then stripped of the outer membrane layer. The pulmonary artery was then divided into smaller fragments and carefully placed at the base of the culture flask. The culture flask was then transferred into the cell incubator for further incubation. Following a period of two hours, the culture flask was inverted, and the cell culture medium containing bovine serum was added. Subsequent changes to the culture medium were made at 2–3 day intervals. Permit the cells to proliferate extensively across the base of the culture flask, and subsequently, transfer or proceed to the subsequent cell experiment. Transfection The following substances were procured from Hanbio (Shanghai, China): PRDX2 siRNA, recombinant PRDX2 (rPRDX2), and negative controls. The transfection of pulmonary artery endothelial cells was conducted using the Advanced DNA/RNA Transfection Reagent (Zeta Life, USA), in accordance with the manufacturer’s instructions.The target sequences utilised in this study are provided in supplementary Table S4. Transmission electron microscope After treatment, cells were aspirated, washed twice with pre-cooled PBS, and incubated with 1 ml trypsin at 37℃ for 2 min. Digestion was stopped by adding complete culture medium. Cells were then transferred to a 15 ml centrifuge tube, centrifuged at 1000 rpm for 5 min at room temperature, resuspended in pre-cooled PBS, transferred to an EP tube, and centrifuged again under the same conditions. The cells were fixed overnight at 4℃ in 2.5% glutaraldehyde, washed three times with PBS for 10 min each at room temperature, and fixed in 1% osmium tetroxide for 1 h at room temperature. The samples were embedded in 10% gelatin, fixed again in glutaraldehyde for 1 h at 4℃, dehydrated in a graded ethanol series (30%-100%), infiltrated with epoxy resin, embedded, sectioned using a Leica UC6 ultramicrotome, and imaged with a transmission electron microscope (H-7650, Hitachi, Japan) at 110 kV. Statistical analysis Data are presented as mean ± standard error of the mean (SEM). Comparisons between two groups were conducted using independent sample t-tests.For comparisons involving more than two groups, one-way ANOVA was used. Two-way ANOVA was used to assess significance for comparisons involving two variables between groups. For in vitro experiments, each group contained at least three biological replicates (n ≥ 3), while in vivo experiments included at least five rats per group (n ≥ 5). Statistical analyses were performed using SPSS 13.0 software, while figures were created with GraphPad Prism 8.0. A p-value of less than 0.05 was deemed to indicate statistical significance. Results PRDX2 levels are elevated in human CTEPH plasma To investigate whether PRDX2 is involved in disease progression in CTEPH, we evaluated differential protein screening in the peripheral blood of CTEPH patients and healthy donors. A total of 114 differentially expressed proteins were detected, comprising 78 upregulated and 36 downregulated proteins (P < 0.05 and fold change ≥ 1.5 or ≤ 1/1.5). Volcano plots and heatmaps showing the expression profiles of the differentially expressed genes are presented in Fig. 1A and B, respectively.The 114 differentially expressed genes were subjected to GO and KEGG enrichment analyses (Fig. 1F and G) to elucidate their potential roles and underlying mechanisms in CTEPH(www.kegg.jp/kegg/kegg1.html). Notably, the difference in the abundance of PRDX2 and vWF protein expression was evident in terms of antioxidant stress and blood coagulation function (Fig. 1C and D). Subsequently, we further validated the expression of PRDX2 and observed that it was upregulated in the peripheral blood of CTEPH patients relative to healthy controls (Fig. 1E).These findings imply that PRDX2 might play a role in the pathogenesis of CTEPH. PRDX2 is elevated in Human CTEPH plasma. (A) Volcano plot depicting differential protein expression between control and CTEPH groups. Red dots represent proteins with significant upregulation (Log2FC > 1, adjusted P < 0.05), and blue dots represent significant downregulation (Log2FC < -1, adjusted P < 0.05).(B) Heatmap showing the scaled intensity of differentially expressed proteins in control and CTEPH groups. The color gradient from blue to red indicates low to high expression levels, respectively.(C) Bar graph comparing the relative abundance of P12191(PRDX2) between control and CTEPH groups. Data are presented as mean ± SEM, with statistical significance indicated by P = 8.86e-03 (unpaired t-test).(D) Box plot showing the relative abundance of vWF protein in control and CTEPH groups. Data are presented as median with interquartile range, and statistical significance is indicated by P = 1.59e-02 (unpaired t-test).(E) Bar graph illustrating PRDX2 levels in plasma from control(n = 33) and CTEPH(n = 36) patients. Data are presented as mean ± SEM, with statistical significance indicated by P < 0.001 (unpaired t-test).(F) Dot plot representing the enrichment analysis of biological processes associated with differentially expressed proteins. The x-axis shows the -Log10(P), and the y-axis lists the biological processes. The size of the dots corresponds to the number of genes involved, and the color represents the -Log10(P) value.(G) Bar graph showing the enrichment analysis of KEGG pathways related to differentially expressed proteins in human CTEPH. The x-axis represents the -Log10(P), and the y-axis lists the pathways. Red bars indicate upregulated pathways. The size of the bars corresponds to the number of genes involved in each pathway.Note: SEM, standard error of the mean; FC, fold change; P, P-value; KEGG, Kyoto Encyclopedia of Genes and Genomes. Establishment of CTEPH rat model To investigate the pathogenesis of CTEPH, we developed an animal model in rats. The modelling was performed according to the developed protocol (Fig. 2A) .The study revealed that the survival rate among the CTEPH group was 50%(Figure S1). The underlying cause of death in all cases was due to misinterpretation of the injected caudal arteriovenous vessels.The rats died of ischaemic necrosis or at the tail end within 1 week of MS injection. No animals died in the control experiment. According to transthoracic echocardiography (TTE) data, the decrease in right ventricular (RV) systolic function, as assessed by tricuspid annular systolic motion (TAPSE), was significantly different between the control and experimental groups at week 12 after microsphere injection (p < 0.05) ( Fig. 2G and H). Cardiac catheterisation showed that RVSP was significantly higher in the experimental group than in the control group in the cardiac catheterisation data at 12 weeks after microsphere injection (p < 0.01) (Figure.2B).The TAPSE/RVSP ratio can be used to assess right ventricle-pulmonary artery coupling and predict the severity of pulmonary hypertension and survival of patients26. In our study, this ratio was decreased in the experimental group, affecting ventricular-arterial coupling (Fig. 2I). Histological examination of the pulmonary vasculature showed that pulmonary embolism resulted in hypertrophy of the pulmonary vessels of the pulmonary arteries in both transverse and longitudinal sections, while Masson’s staining suggested fibrotic lesions in the pulmonary arteries (Figure.2 C-2E). Further immunofluorescence of the pulmonary arteries was performed, which clearly indicated that the walls of the pulmonary arteries were significantly thickened compared to the normal group (Fig. 2F). The above data indicated that the CTEPH model could be induced by external microsphere infusion. Establishment and Characterization of a Rat Model for CTEPH.(A) Experimental design of rat model of CTEPH induced by microsphere injection.(B) Right ventricular systolic pressure (RVSP) measurements via cardiac catheterization at 12 weeks post-injection(n = 6).(C) Histological analysis of pulmonary arteries (PA) showing axial and coronal sections in both control and CTEPH groups. Masson’s trichrome and immunohistochemistry (IHC) for α-smooth muscle actin (α-SMA) are also depicted. Scale bars represent 50 μm.(D) Medial thickness index of pulmonary arteries, expressed as a percentage of vessel area(n = 6). (E) Percentage of fibrotic area in the vessel wall(n = 6). (F) Immunofluorescence staining for α-SMA (red) and nuclei (DAPI, blue) in pulmonary arteries. Scale bars represent 50 μm.(G) Representative echocardiographic images showing tricuspid annular plane systolic excursion (TAPSE) in control and CTEPH rats.(H) Quantification of TAPSE in control and CTEPH rats(n = 8). (I) Ratio of TAPSE to RVSP, indicating right ventricular-pulmonary arterial coupling(n = 8).Note: Data are presented as mean ± SEM. ***p < 0.001,**p < 0.01. PRDX2 is compensatory elevated in CTEPH of microspheres induced in vivo and in vitro We investigated whether PRDX2 is involved in the progression of CTEPH. First, we performed immunofluorescence to show that highly expressed PRDX2 was mainly found in the pulmonary vascular endothelium of CTEPH rats (Fig. 3A), and endothelial cell immunofluorescence suggested that PRDX2 was mainly localised in the cytoplasm (Fig. 3B). Next, we examined mRNA and protein levels in lung tissue from CTEPH and control rats, and significant differences in PRDX2 protein expression and mRNA levels were observed between CTEPH and control groups (Fig. 3C and E). PRDX2 is an antioxidant enzyme which protects against oxidative stress. owever, the expression and activity of PRDX2 following microsphere-induced pulmonary embolism are unclear. To investigate this, lung tissues were collected from rats at 3, 6 and 12 weeks post-embolism, and PRDX2 protein expression and activity were assessed. Our results revealed that PRDX2 expression increased progressively over time following embolism(Figure S2). This temporal upregulation suggests that PRDX2 is elevated in a compensatory manner during the development of pulmonary thromboembolism.Therefore, we further investigated the potential mechanism of PRDX2 upregulation in CTEPH. Validation in primary pulmonary artery endothelial cells showed that PRDX2 protein expression and mRNA levels were consistent with lung tissue results (Fig. 3F and H). Collectively, these findings indicate that CTEPH induced by microspheres in both in vivo and in vitro settings is associated with elevated PRDX2 protein levels. Expression and Localization of PRDX2 in a Rat Model of CTEPH. (A) Immunofluorescence staining for PRDX2 (red) and von Willebrand factor (vWF, green) in lung tissues from control and CTEPH rats. Nuclei were counterstained with DAPI (blue). Scale bars represent 50 μm.(B) Immunofluorescence staining for PRDX2 (red) and DAPI (blue) in lung tissues from control and CTEPH rats. Scale bars represent 50 μm.(C) Western blot analysis of PRDX2 protein expression in lung tissues from control and CTEPH rats. (D) Quantification of PRDX2 protein expression normalized to tubulin. (E) Quantitative RT-PCR analysis of PRDX2 mRNA expression in lung tissues from control and CTEPH rats. (F) Western blot analysis of PRDX2 protein expression in primary arterial endothelial cells (PAECs) from control and CTEPH rats. (G) Quantification of PRDX2 protein expression normalized to tubulin in PAECs. (H) Quantitative RT-PCR analysis of PRDX2 mRNA expression in PAECs from control and CTEPH rats. Note: Data are presented as mean ± SEM. **p < 0.01 compared to control.PAECs, primary arterial endothelial cells.n = 6 replicates/group. CTEPH and inflammation: NF-κB pathway activation and cytokine upregulation CTEPH is characterized by persistent inflammation, which is vital for disease progression. In this study, we examined the expression of key inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, in the pulmonary tissues of CTEPH rats. We employed immunohistochemistry, immunofluorescence, and qRT-PCR to comprehensively assess the levels of these cytokines.Our results demonstrated a significant upregulation of IL-1β, IL-6, and TNF-α in the pulmonary tissues of CTEPH rats compared to the control group (Fig. 4A and C). Similar findings were observed in the pulmonary artery endothelial cells (PAECs) of these rats (Fig. 4D). These observations suggest that inflammation is a critical component of the pathophysiology of CTEPH.To further elucidate the underlying mechanisms, we treated CTEPH PAECs with the NF-κB pathway inhibitor BAY-11-7085. This treatment led to a significant reduction in the expression levels of NF-κB, IL-1β, IL-6, and TNF-α (Fig. 4E). These results suggest that the NF-κB signaling pathway is activated in CTEPH and promotes the upregulation of inflammatory cytokines. Inflammatory Response and NF-κB Pathway Activation in a Rat Model of CTEPH (A) Immunohistochemistry staining for IL-1β, IL-6, and TNF-α in lung tissues from control and CTEPH rats. Scale bars represent 50 μm.(B) Immunofluorescence staining for IL-1β (red), IL-6 (red), and TNF-α (red) in lung tissues from control and CTEPH rats. Nuclei were counterstained with DAPI (blue). Scale bars represent 50 μm.(C) Quantitative RT-PCR analysis of IL-1β, IL-6, and TNF-α mRNA expression in lung tissues from control and CTEPH rats. (D) Immunofluorescence staining for IL-1β(green), IL-6(green), and TNF-α(green) in primary arterial endothelial cells (PAECs) from control and CTEPH rats. Nuclei were counterstained with DAPI (blue). Scale bars represent 50 μm.(E) Quantitative RT-PCR analysis of IL-1β, IL-6, and TNF-α mRNA expression in PAECs treated with or without the NF-κB inhibitor BAY-11-7085. Note: Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 compared to control.PAECs, primary arterial endothelial cells.n = 6 replicates/group. Overexpression of PRDX2 alleviates MS-Induced CTEPH To elucidate the impact of PRDX2 in endothelial cells on the development of CTEPH and associated inflammation.We transfected PAECs with PRDX2-specific small interfering RNA (siRNA) to silence PRDX2 expression and with a PRDX2 overexpression construct to enhance its expression. The efficiency of transfection was confirmed by Western blotting, showing successful modulation of PRDX2 protein levels in the cells (Fig. 5A and B).Silencing PRDX2 in PAECs led to a significant increase in the expression of inflammatory markers NF-κB, IL-1β, IL-6, and TNF-α, indicating a pro-inflammatory state. Conversely, overexpression of PRDX2 resulted in a marked reduction in these inflammatory markers, suggesting a protective effect against inflammation(Fig. 5C).Further investigation into the underlying mechanisms revealed differential expression of mitophagy-related proteins. In PRDX2-silenced PAECs, the levels of LC3II/I and Beclin-1 were increased, while p62 levels were decreased, indicating an increase in autophagy flux. TEM analysis showed that mitochondria in these cells were more likely to form mitochondria fused with lysosomes, suggesting enhanced mitochondrial degradation (Fig. 5D and E).In contrast, overexpression of PRDX2 normalized the expression of these autophagy markers and restored mitochondrial morphology. TEM images showed that mitochondria in PRDX2-overexpressing PAECs exhibited a more intact structure, with fewer mitolysosomes observed (Fig. 5F).We observed that CTEPH-exposed pulmonary arterial endothelial cells exhibited a pronounced increase in ROS generation. Silencing PRDX2 further exacerbated ROS accumulation, whereas PRDX2 overexpression markedly attenuated it. These findings indicate that PRDX2 plays a crucial role in modulating oxidative stress under CTEPH conditions(Figure S3). Effects of PRDX2 Modulation on Inflammatory Response and Mitophagy in PAECs from CTEPH Rats. (A) Western blot analysis of PRDX2protein expression in PAECs transfected with control, CTEPH, siPRDX2, and OE-PRDX2. (B) Quantification of PRDX2 relative protein expression levels normalized to tubulin.(C)Relative mRNA expression levels of inflammatory cytokines IL-1β, IL-6, TNF-α, and NF-κB in different treatment groups. Expression levels were normalized to β-actin and are presented as fold change relative to control. (D) Western blot analysis of LC3 II/I, Beclin-1 and P62 protein expression in PAECs transfected with control, CTEPH, siPRDX2, and OE-PRDX2.(E Quantification of LC3 II/I, Beclin-1 and P62 relative protein expression levels normalized to tubulin. (F) Electron microscopy images of mitochondria in PAECs from control, CTEPH, CTEPH + siPRDX2, and CTEPH + OE-PRDX2 groups. Scale bars represent 2 μm (overview) and 500 nm (inset).Note: Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.n = 6 replicates/group. To clarify the in vivo effects of PRDX2 overexpression in chronic thromboembolic pulmonary hypertension (CTEPH), we employed an adenoviral vector to overexpress PRDX2 in rats, as illustrated in Fig. 6A. Our findings revealed that rats overexpressing PRDX2 exhibited attenuated progression of CTEPH. Furthermore, rats with PRDX2 overexpression exhibited a significantly lower mortality rate (Figure S4).Specifically, hemodynamic assessments showed significant improvements in right ventricular systolic pressure (RVSP) (Fig. 6B and C) and tricuspid annular plane systolic excursion (TAPSE) (Fig. 6D and F). Additionally, histological analyses demonstrated reduced pulmonary vascular remodeling in PRDX2-overexpressing rats (Fig. 6G and H). AAV-mediated PRDX2 overexpression in the lungs of treated animals was further verified by Western blot and qPCR(Fig. 6I and K). These results highlight the protective role of PRDX2 overexpression in mitigating CTEPH pathophysiology. Effects of Overexpressing PRDX2 on CTEPH Progression in Rats. (A) Schematic representation of the experimental timeline for the administration of adeno-associated virus (AAV) carrying an empty vector or PRDX2 overexpression construct in rats. (B) Right ventricular systolic pressure (RVSP) measurements via cardiac catheterization at 12 weeks post-injection in rats treated with AAV6-empty-vector and AAV6-OE-PRDX2. (C) RVSP measurements in rats treated with AAV6-empty-vector and AAV6-OE-PRDX2(n=8).(D and E)Representative echocardiographic images showing tricuspid annular plane systolic excursion (TAPSE) in rats treated with AAV6-empty-vector and AAV6-OE-PRDX2.(F) Quantification of TAPSE in rats treated with AAV6-empty-vector and AAV6-OE-PRDX2(n=8).(G)This histological analysis of pulmonary arteries, using H&E and Masson’s trichrome staining, was performed on rats treated with either an AAV6 empty vector and an AAV6 overexpressing PRDX2.Scale bars represent 50 μm.(H) Quantification of medial thickness index expressed as a percentage of vessel area(n=8). (I-J)Western blot analysis of PRDX2 protein expression in lung tissues treated with AAV6-empty-vector and AAV6-OE-PRDX2(n=8).(K)AAV-induced PRDX2 overexpression in lung tissue was confirmed by qPCR༈n=8༉. Note: Data are presented as mean ± SEM. **p < 0.01,***p < 0.001. Discussion Pulmonary artery thrombus serves as a pivotal factor in driving pulmonary vascular remodeling in cases of chronic thromboembolic pulmonary hypertension3. The persistent insolubility of the thrombus triggers chronic sterile inflammation, with modulation of inflammation in endothelial cells playing a crucial role in disease progression27,28. In this study, we aimed to identify novel mechanisms underlying the development of chronic thromboembolic pulmonary hypertension. Utilizing proteomic analysis of peripheral blood samples from CTEPH patients and healthy controls, we identified PRDX2 as a significantly upregulated candidate molecule. Further investigation in CTEPH animal models revealed that pulmonary artery endothelial PRDX2 plays a pivotal role in CTEPH pathogenesis, with its overexpression attenuating the inflammatory response in cellular models. Our study demonstrates that targeting endothelial PRDX2 induces mitochondrial autophagy, thereby alleviating pulmonary artery endothelial cell dysfunction. These findings highlight a novel function of PRDX2 in regulating mitochondrial autophagy in endothelial cells and suggest that PRDX2 may represent a promising therapeutic target for CTEPH treatment. Animal models of CTEPH have limitations in accurately simulating human pathophysiological characteristics. Current CTEPH models include pigs, dogs, rabbits, and rodents (rats and mice)29–31. However, pigs and dogs are expensive and challenging to maintain, restricting their widespread use. Rats are the most commonly used species for modeling pulmonary hypertension, and CTEPH models can be established via various methods, including autologous thrombus injection32, extracorporeal microsphere injection33,34, and inferior vena cava ligation31.Autologous thrombus injection requires manual shearing of the thrombus, which is uncontrollable in size, and necessitates multiple adjuvants such as penicillin to prevent infection and tranexamic acid to inhibit fibrinolysis32. In contrast, extracorporeal microsphere injection is a simpler and more convenient approach. Previous studies have demonstrated that multiple intravenous injections of soluble sodium alginate microspheres over 4 days, followed by 18 weeks of observation, resulted in stable increases in pulmonary arterial pressure, decreased exercise tolerance, and endothelial dysfunction in rats35. In the present study, we attempted a single injection of 1 ml of amino cross-linked polystyrene microspheres into the tail vein, inducing pulmonary embolism with characteristic pathological changes, including small artery hypertrophy, fibrotic lesions in pulmonary arteries, increased right ventricular pressure, and inflammatory infiltration of lung tissue and endothelial cells. This method recapitulated the pathophysiological features of chronic pulmonary thromboembolism observed in previous microsphere injection studies. Our model is easy to produce, exhibits typical pathological features, and is well-suited for investigating the roles of various cytokines and inflammatory mediators in the pathophysiology of pulmonary thromboembolism. Inflammatory responses are crucial in the pathogenesis of pulmonary hypertension1. Pro-inflammatory cytokines such as IL-1β, IL-6, and MCP-1, released from pulmonary artery endothelial cells, can promote smooth muscle cell proliferation in pulmonary arterial hypertension by mediating endothelial-to-mesenchymal transition and recruiting inflammatory cells25. Our study corroborated these findings. Using a combination of qRT-PCR, Western blotting, and immunofluorescence staining, we demonstrated that the expression levels of IL-1β, IL-6, and TNF-α were significantly elevated in the rat CTEPH model.PRDX2, a member of the peroxidase family, is widely distributed in cells and has multiple biological functions associated with the development of various diseases18. PRDX2 plays a key role in regulating cellular oxidative stress, anti-inflammatory responses, and cell signaling36. Our study revealed that PRDX2 inhibition enhances the production of inflammatory factors by pulmonary artery endothelial cells, whereas PRDX2 activation modulates the expression of multiple inflammation-related genes via the NF-κB pathway. Our findings highlight the critical role of PRDX2 in the pathogenesis of pulmonary hypertension, demonstrating that it attenuates the inflammatory response by inhibiting the release of inflammatory factors through NF-κB pathway regulation. This study provides a novel target and theoretical basis for the treatment of pulmonary hypertension. The pathophysiology of CTEPH is characterized by the formation and obstruction of thrombi within the pulmonary arteries37. Following thrombus formation, ECs experience mechanical injury and are stimulated by inflammatory factors, leading to endothelial dysfunction27. The integrity of ECs function relies heavily on mitochondrial health, with mitophagy (mitochondrial autophagy) serving as a crucial mechanism for maintaining mitochondrial quality38. When mitophagy is dysregulated, damaged mitochondria accumulate, exacerbating mitochondrial dysfunction9. For instance, loss of mitochondrial membrane potential, mitochondrial DNA damage, and impaired mitochondrial respiratory chain function can all contribute to increased oxidative stress and inflammation in ECs, thereby driving pulmonary vascular remodeling39. Moreover, chronic or excessive inflammation can suppress mitophagy, leading to the accumulation of damaged mitochondria, increased oxidative stress, and cell death, which in turn further amplifies the inflammatory response40. Our study revealed that inflammation-related signaling molecules, such as TNF-α and IL-1β, IL-6, can directly or indirectly influence the expression of mitophagy-related proteins. Activation of PRDX2 in endothelial cells can modulate mitophagy in an inflammatory context and affect the expression of several inflammation-related genes. Our study demonstrates that overexpression of PRDX2 exerts a protective effect against the progression of CTEPH in vivo. Specifically, overexpression of PRDX2 significantly improved key hemodynamic parameters and attenuated pulmonary vascular remodeling. These findings underscore the potential therapeutic utility of PRDX2 in mitigating the pathophysiology of CTEPH and highlight its role as a promising target for future interventions. Our study offers valuable insights into the role of PRDX2 in CTEPH; however, it is important to recognize several limitations. Firstly, while the use of a single injection of microspheres to induce CTEPH in rats effectively produces characteristic pathological changes, this method may not fully replicate the complex human pathophysiology of the disease. The model primarily mimics chronic pulmonary thromboembolism but does not encompass the multifactorial etiology seen in human CTEPH, which includes genetic predisposition and comorbid conditions such as heart failure or chronic lung disease. Secondly, the relatively small sample size in our human study may limit the statistical power and generalizability of our findings. Larger cohorts are necessary to validate the differential expression of PRDX2 and other proteins identified in our proteomic analysis. Lastly, the potential therapeutic implications of targeting PRDX2 for CTEPH treatment require further investigation. Future studies should explore the efficacy and safety of PRDX2-based therapies in preclinical models and clinical trials. Despite these limitations, our study identifies PRDX2 as a promising therapeutic target and establishes a basis for further research into the pathophysiology and treatment of CTEPH. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements I would like to express my gratitude to the research team of the project: Zhiyu Zeng, Feng Huang, Hong Wen, Xiaoyan Lan, Yiming Xie, Xiaobing wu, Fengxia Wu, Xing Chen and Huilei Zheng. Author contributions ZYZ and FH conceived and designed the study. CG and HW participated in the experimental design. CG, XYL, YMX, FXW, HLZ and XC performed the experiments. CG, XYL and XBW analysed the data. CG and XYL wrote the manuscript, and all authors reviewed, and have read and approved the final manuscript. Funding This study was supported by the Guangxi Key Laboratory of Precision Medicine in Cardio-cerebrovascular Diseases Control and Prevention(grant no. 22-035-18), the Guangxi Clinical Research Center for Cardio-cerebrovascular Diseases (grant no. AD17129014) ,the Guangxi Science and technology planning project༈Guike AB24010178), the Guangxi Natural Science Foundation Project(2025GXNSFAA069092), Guangxi University Young and Middle-aged Teachers Scientific Research Basic Ability Enhancement Program(2025KY0134 and 2024KY1774), Guangxi Higher Education Undergraduate Teaching Reform Project(2024JGA154). Data availability Data is provided within the manuscript or supplementary information files. Declarations Competing interests The authors declare no competing interests. Ethics approval and consent to participate All methods are reported in accordance with ARRIVE guidelines (https://arriveguidelines.org). Protocols involving human were approved by The Medical Ethics Committee of The First Affiliated Hospital of Guangxi Medical University(Nanning, China; approval no. 2024-S946-01). All animal procedures were approved by the Animal Ethics Committee of Guangxi Medical University and were conducted in accordance with the ethical guidelines for the use of experimental animals(Nanning, China; approval no. 202401001). Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Chen Gong, Xiaoyan Lan and Yiming Xie contributed equally to this work. Contributor Information Feng Huang, Email: huangfeng3000@126.com. Zhiyu Zeng, Email: zengzhiyu@gxmu.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement Data is provided within the manuscript or supplementary information files.